Heron Therapeutics Inc (HRTX)

Over the past six months, Heron Therapeutics' stock has experienced several notable events. The company reported Q4 2025 net revenue of $154.9 million and Q3 2025 net revenue of $38.2 million. Q1 2026 financial results are scheduled to be reported on May 11, 2026. The stock has seen a general decline of 42.86% from May 8, 2025, to May 7, 2026, but has shown recent uptrends. Heron Therapeutics adopted a Section 382 Rights Plan to protect its net operating loss carryforwards. A settlement with Mylan related to CINVANTI and APONVIE patent litigations was announced. Changes in beneficial ownership by an insider or major shareholder contributed to an upbeat sentiment.

While specific seasonal patterns for Heron Therapeutics' products are not explicitly detailed, recent financial reports indicate strong year-over-year growth in demand for its key products. The Acute Care franchise demonstrated significant revenue growth, reflecting increased adoption and commercial acceleration. CINVANTI also saw an increase in unit demand and net revenue. This suggests a growing demand for their therapeutic solutions, but without further data, a clear seasonal pattern cannot be definitively established.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on enhancing patient care through the development and commercialization of therapeutic solutions, operating in the Healthcare sector, specifically in the Biotechnology & Drugs industry. The company utilizes its Biochronomer® drug delivery technology to create extended-release formulations. Its product portfolio includes ZYNRELEF, a dual-acting local anesthetic for postoperative pain management; APONVIE, an intravenous formulation of aprepitant for the prevention of postoperative nausea and vomiting; CINVANTI, an intravenous formulation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting; and SUSTOL, an extended-release 5-HT3 receptor antagonist for the prevention of nausea and vomiting associated with chemotherapy.

Heron Therapeutics, Inc. is headquartered in Cary, North Carolina, having relocated from San Diego, California, effective January 1, 2025. The company's operations and commercialization efforts are primarily focused within the United States.

In the past year, Heron Therapeutics' brand reputation has generally been positive, with a consensus analyst rating ranging from "Hold" to "Buy." Analysts have noted a significant potential upside for the stock, driven by expected improvements in earnings and a promising product pipeline. The company is focused on improving patient care through innovative therapies in acute care and oncology. News coverage has largely focused on financial results, product growth, and corporate developments.

Heron Therapeutics, Inc. is primarily owned by institutional shareholders (82.99%) and insiders (66.23%), with a smaller percentage held by retail investors (0.00%). As of May 6, 2026, 175 institutional owners and shareholders hold a total of 166,703,868 shares. Major institutional owners include Rubric Capital Management LP, Clearline Capital LP, Adage Capital Partners Gp, L.l.c., BlackRock, Inc., Vanguard Group Inc, Velan Capital Investment Management LP, Vanguard Capital Management Llc, Millennium Management Llc, Palisade Capital Management Llc/nj and Tang Capital Management Llc. Spch LLC is the largest individual shareholder, owning 38.17 million shares, representing 20.25% of the company.